High-Impact Form 4 Intelligence
Real-time SEC insider trading data with advanced filtering. Free beta.
Total Buys (Filtered)
$0
$0
Total Sells (Filtered)
$75.5M
$75,509,750
| Ticker | Company | Reporting Owner | Date | Value (USD) | Type | Form 4 |
|---|---|---|---|---|---|---|
|
TEVA
S
TEVA PHARMACEUTICAL INDUSTRIES LTD
Savage Brian
• Officer • Interim Chief Legal Officer
Sell to Cover
2026-03-05
$35,690
|
||||||
| TEVA |
TEVA PHARMACEUTICAL INDUSTRIES LTD
|
Officer • Interim Chief Legal Officer
Sell to Cover
|
2026-03-05 | $35,690 | S | Form 4 |
|
TEVA
S
TEVA PHARMACEUTICAL INDUSTRIES LTD
Jover Placid
• Officer • See "Remarks"
10b5-1 SellΔOwn -67.6%
2026-03-05
$448,108
|
||||||
| TEVA |
TEVA PHARMACEUTICAL INDUSTRIES LTD
|
Officer • See "Remarks"
10b5-1 SellΔOwn -67.6%
|
2026-03-05 | $448,108 | S | Form 4 |
|
TEVA
S
TEVA PHARMACEUTICAL INDUSTRIES LTD
Shields Matthew
• Officer • EVP, Global Operations
10b5-1 SellΔOwn -63.4%
2026-03-05
$547,705
|
||||||
| TEVA |
TEVA PHARMACEUTICAL INDUSTRIES LTD
|
Officer • EVP, Global Operations
10b5-1 SellΔOwn -63.4%
|
2026-03-05 | $547,705 | S | Form 4 |
|
TEVA
S
TEVA PHARMACEUTICAL INDUSTRIES LTD
Fox Christine
• Officer • EVP, U.S. Commercial
Sell to Cover
2026-03-05
$250,940
|
||||||
| TEVA |
TEVA PHARMACEUTICAL INDUSTRIES LTD
|
Officer • EVP, U.S. Commercial
Sell to Cover
|
2026-03-05 | $250,940 | S | Form 4 |
|
TEVA
S
TEVA PHARMACEUTICAL INDUSTRIES LTD
Hughes Eric A
• Officer • See "Remarks"
Sell to Cover
2026-03-05
$301,895
|
||||||
| TEVA |
TEVA PHARMACEUTICAL INDUSTRIES LTD
|
Officer • See "Remarks"
Sell to Cover
|
2026-03-05 | $301,895 | S | Form 4 |
|
TEVA
S
TEVA PHARMACEUTICAL INDUSTRIES LTD
Daniell Richard
• Officer • EVP, Europe Commercial
10b5-1 SellΔOwn -16.8%
2026-03-05
$547,705
|
||||||
| TEVA |
TEVA PHARMACEUTICAL INDUSTRIES LTD
|
Officer • EVP, Europe Commercial
10b5-1 SellΔOwn -16.8%
|
2026-03-05 | $547,705 | S | Form 4 |
| TEVA |
TEVA PHARMACEUTICAL INDUSTRIES LTD
|
CEO
Sell to Cover
|
2026-03-05 | $634,160 | S | Form 4 |
| TEVA |
TEVA PHARMACEUTICAL INDUSTRIES LTD
|
CEO
Sell to Cover
|
2026-03-04 | $759,442 | S | Form 4 |
|
TEVA
S
TEVA PHARMACEUTICAL INDUSTRIES LTD
Daniell Richard
• Officer • EVP, Europe Commercial
10b5-1 SellΔOwn -21.4%
2026-03-04
$1,087,950Large
|
||||||
| TEVA |
TEVA PHARMACEUTICAL INDUSTRIES LTD
|
Officer • EVP, Europe Commercial
10b5-1 SellΔOwn -21.4%
|
2026-03-04 | $1,087,950Large | S | Form 4 |
|
TEVA
S
TEVA PHARMACEUTICAL INDUSTRIES LTD
Savage Brian
• Officer • Interim Chief Legal Officer
Sell to CoverΔOwn -12.3%
2026-03-04
$38,503
|
||||||
| TEVA |
TEVA PHARMACEUTICAL INDUSTRIES LTD
|
Officer • Interim Chief Legal Officer
Sell to CoverΔOwn -12.3%
|
2026-03-04 | $38,503 | S | Form 4 |
|
TEVA
S
TEVA PHARMACEUTICAL INDUSTRIES LTD
Savage Brian
• Officer • Interim Chief Legal Officer
Sell to CoverΔOwn -19.4%
2026-03-04
$48,340
|
||||||
| TEVA |
TEVA PHARMACEUTICAL INDUSTRIES LTD
|
Officer • Interim Chief Legal Officer
Sell to CoverΔOwn -19.4%
|
2026-03-04 | $48,340 | S | Form 4 |
|
TEVA
S
TEVA PHARMACEUTICAL INDUSTRIES LTD
Fox Christine
• Officer • EVP, U.S. Commercial
Sell to CoverΔOwn -10.8%
2026-03-04
$295,362
|
||||||
| TEVA |
TEVA PHARMACEUTICAL INDUSTRIES LTD
|
Officer • EVP, U.S. Commercial
Sell to CoverΔOwn -10.8%
|
2026-03-04 | $295,362 | S | Form 4 |
|
TEVA
S
TEVA PHARMACEUTICAL INDUSTRIES LTD
Hughes Eric A
• Officer • See "Remarks"
Sell to CoverΔOwn -10.4%
2026-03-04
$366,102
|
||||||
| TEVA |
TEVA PHARMACEUTICAL INDUSTRIES LTD
|
Officer • See "Remarks"
Sell to CoverΔOwn -10.4%
|
2026-03-04 | $366,102 | S | Form 4 |
|
TEVA
S
TEVA PHARMACEUTICAL INDUSTRIES LTD
Daniell Richard
• Officer • EVP, Europe Commercial
10b5-1 SellΔOwn -30.4%
2026-03-04
$1,231,310Large
|
||||||
| TEVA |
TEVA PHARMACEUTICAL INDUSTRIES LTD
|
Officer • EVP, Europe Commercial
10b5-1 SellΔOwn -30.4%
|
2026-03-04 | $1,231,310Large | S | Form 4 |
|
TEVA
S
TEVA PHARMACEUTICAL INDUSTRIES LTD
Daniell Richard
• Officer • EVP, Europe Commercial
10b5-1 SellΔOwn -14.2%
2026-03-04
$664,256
|
||||||
| TEVA |
TEVA PHARMACEUTICAL INDUSTRIES LTD
|
Officer • EVP, Europe Commercial
10b5-1 SellΔOwn -14.2%
|
2026-03-04 | $664,256 | S | Form 4 |
|
TEVA
S
TEVA PHARMACEUTICAL INDUSTRIES LTD
Savage Brian
• Officer • Interim Chief Legal Officer
Sell to CoverΔOwn -30.3%
2026-03-03
$41,227
|
||||||
| TEVA |
TEVA PHARMACEUTICAL INDUSTRIES LTD
|
Officer • Interim Chief Legal Officer
Sell to CoverΔOwn -30.3%
|
2026-03-03 | $41,227 | S | Form 4 |
|
TEVA
S
TEVA PHARMACEUTICAL INDUSTRIES LTD
Francis Richard D
• CEO
Sell to Cover
2026-03-03
$1,000,018Large
|
||||||
| TEVA |
TEVA PHARMACEUTICAL INDUSTRIES LTD
|
CEO
Sell to Cover
|
2026-03-03 | $1,000,018Large | S | Form 4 |
|
TEVA
S
TEVA PHARMACEUTICAL INDUSTRIES LTD
Francis Richard D
• CEO
Sell to CoverΔOwn -26.9%
2026-03-03
$13,333,314MEGA
|
||||||
| TEVA |
TEVA PHARMACEUTICAL INDUSTRIES LTD
|
CEO
Sell to CoverΔOwn -26.9%
|
2026-03-03 | $13,333,314MEGA | S | Form 4 |
|
TEVA
S
TEVA PHARMACEUTICAL INDUSTRIES LTD
Daniell Richard
• Officer • EVP, Europe Commercial
10b5-1 SellΔOwn -56.3%
2026-03-03
$2,014,404Large
|
||||||
| TEVA |
TEVA PHARMACEUTICAL INDUSTRIES LTD
|
Officer • EVP, Europe Commercial
10b5-1 SellΔOwn -56.3%
|
2026-03-03 | $2,014,404Large | S | Form 4 |
|
TEVA
S
TEVA PHARMACEUTICAL INDUSTRIES LTD
Daniell Richard
• Officer • EVP, Europe Commercial
10b5-1 SellΔOwn -35.1%
2026-03-03
$2,159,538Large
|
||||||
| TEVA |
TEVA PHARMACEUTICAL INDUSTRIES LTD
|
Officer • EVP, Europe Commercial
10b5-1 SellΔOwn -35.1%
|
2026-03-03 | $2,159,538Large | S | Form 4 |
|
TEVA
S
TEVA PHARMACEUTICAL INDUSTRIES LTD
Hughes Eric A
• Officer • See "Remarks"
Sell to CoverΔOwn -48.5%
2026-03-03
$390,811
|
||||||
| TEVA |
TEVA PHARMACEUTICAL INDUSTRIES LTD
|
Officer • See "Remarks"
Sell to CoverΔOwn -48.5%
|
2026-03-03 | $390,811 | S | Form 4 |
|
TEVA
S
TEVA PHARMACEUTICAL INDUSTRIES LTD
Hughes Eric A
• Officer • See "Remarks"
Sell to CoverΔOwn -44.5%
2026-03-03
$2,222,640Large
|
||||||
| TEVA |
TEVA PHARMACEUTICAL INDUSTRIES LTD
|
Officer • See "Remarks"
Sell to CoverΔOwn -44.5%
|
2026-03-03 | $2,222,640Large | S | Form 4 |
|
TEVA
S
TEVA PHARMACEUTICAL INDUSTRIES LTD
Kalif Eliyahu Sharon
• CFO
10b5-1 SellΔOwn -85.8%
2026-02-26
$11,634,708MEGA
|
||||||
| TEVA |
TEVA PHARMACEUTICAL INDUSTRIES LTD
|
CFO
10b5-1 SellΔOwn -85.8%
|
2026-02-26 | $11,634,708MEGA | S | Form 4 |
|
TEVA
S
TEVA PHARMACEUTICAL INDUSTRIES LTD
Francis Richard D
• CEO
10b5-1 SellΔOwn -32.1%
2026-02-15
$9,792,268Whale
|
||||||
| TEVA |
TEVA PHARMACEUTICAL INDUSTRIES LTD
|
CEO
10b5-1 SellΔOwn -32.1%
|
2026-02-15 | $9,792,268Whale | S | Form 4 |
|
TEVA
S
TEVA PHARMACEUTICAL INDUSTRIES LTD
Francis Richard D
• CEO
10b5-1 SellΔOwn -37.3%
2026-02-15
$5,532,531Whale
|
||||||
| TEVA |
TEVA PHARMACEUTICAL INDUSTRIES LTD
|
CEO
10b5-1 SellΔOwn -37.3%
|
2026-02-15 | $5,532,531Whale | S | Form 4 |
|
TEVA
S
TEVA PHARMACEUTICAL INDUSTRIES LTD
MIGNONE ROBERTO
• Director
Discretionary SellΔOwn -17.4%
2025-12-16
$2,340,646Large
|
||||||
| TEVA |
TEVA PHARMACEUTICAL INDUSTRIES LTD
|
Director
Discretionary SellΔOwn -17.4%
|
2025-12-16 | $2,340,646Large | S | Form 4 |
|
TEVA
S
TEVA PHARMACEUTICAL INDUSTRIES LTD
Weiss Amir
• Officer • Chief Accounting Officer
Discretionary SellΔOwn -68.5%
2025-12-16
$371,504
|
||||||
| TEVA |
TEVA PHARMACEUTICAL INDUSTRIES LTD
|
Officer • Chief Accounting Officer
Discretionary SellΔOwn -68.5%
|
2025-12-16 | $371,504 | S | Form 4 |
|
TEVA
M
TEVA PHARMACEUTICAL INDUSTRIES LTD
Daniell Richard
• Officer • Exec. VP, European Commercial
Other
2025-12-09
$255,037
|
||||||
| TEVA |
TEVA PHARMACEUTICAL INDUSTRIES LTD
|
Officer • Exec. VP, European Commercial
Other
|
2025-12-09 | $255,037 | M | Form 4 |
|
TEVA
M
TEVA PHARMACEUTICAL INDUSTRIES LTD
Sabag Mark
• Officer • See "Remarks"
Equity Compensation
2025-12-09
$0
|
||||||
| TEVA |
TEVA PHARMACEUTICAL INDUSTRIES LTD
|
Officer • See "Remarks"
Equity Compensation
|
2025-12-09 | $0 | M | Form 4 |
|
TEVA
S
TEVA PHARMACEUTICAL INDUSTRIES LTD
Sabag Mark
• Officer • See "Remarks"
Discretionary SellΔOwn -65.0%
2025-12-09
$2,817,677Large
|
||||||
| TEVA |
TEVA PHARMACEUTICAL INDUSTRIES LTD
|
Officer • See "Remarks"
Discretionary SellΔOwn -65.0%
|
2025-12-09 | $2,817,677Large | S | Form 4 |
|
TEVA
S
TEVA PHARMACEUTICAL INDUSTRIES LTD
Sabag Mark
• Officer • See "Remarks"
Discretionary SellΔOwn -44.0%
2025-12-09
$3,413,078Large
|
||||||
| TEVA |
TEVA PHARMACEUTICAL INDUSTRIES LTD
|
Officer • See "Remarks"
Discretionary SellΔOwn -44.0%
|
2025-12-09 | $3,413,078Large | S | Form 4 |
|
TEVA
M
TEVA PHARMACEUTICAL INDUSTRIES LTD
Sabag Mark
• Officer • See "Remarks"
Other
2025-12-09
$2,209,454Large
|
||||||
| TEVA |
TEVA PHARMACEUTICAL INDUSTRIES LTD
|
Officer • See "Remarks"
Other
|
2025-12-09 | $2,209,454Large | M | Form 4 |
|
TEVA
M
TEVA PHARMACEUTICAL INDUSTRIES LTD
Daniell Richard
• Officer • Exec. VP, European Commercial
Equity Compensation
2025-12-09
$0
|
||||||
| TEVA |
TEVA PHARMACEUTICAL INDUSTRIES LTD
|
Officer • Exec. VP, European Commercial
Equity Compensation
|
2025-12-09 | $0 | M | Form 4 |
|
TEVA
M
TEVA PHARMACEUTICAL INDUSTRIES LTD
Daniell Richard
• Officer • Exec. VP, European Commercial
Equity Compensation
2025-12-09
$0
|
||||||
| TEVA |
TEVA PHARMACEUTICAL INDUSTRIES LTD
|
Officer • Exec. VP, European Commercial
Equity Compensation
|
2025-12-09 | $0 | M | Form 4 |
|
TEVA
S
TEVA PHARMACEUTICAL INDUSTRIES LTD
Daniell Richard
• Officer • Exec. VP, European Commercial
Discretionary SellΔOwn -70.5%
2025-12-09
$3,311,126Large
|
||||||
| TEVA |
TEVA PHARMACEUTICAL INDUSTRIES LTD
|
Officer • Exec. VP, European Commercial
Discretionary SellΔOwn -70.5%
|
2025-12-09 | $3,311,126Large | S | Form 4 |
|
TEVA
M
TEVA PHARMACEUTICAL INDUSTRIES LTD
Daniell Richard
• Officer • Exec. VP, European Commercial
Other
2025-12-09
$1,869,505Large
|
||||||
| TEVA |
TEVA PHARMACEUTICAL INDUSTRIES LTD
|
Officer • Exec. VP, European Commercial
Other
|
2025-12-09 | $1,869,505Large | M | Form 4 |
|
TEVA
M
TEVA PHARMACEUTICAL INDUSTRIES LTD
Lichtenstein Chen
• Director
Equity Compensation
2025-12-02
$0
|
||||||
| TEVA |
TEVA PHARMACEUTICAL INDUSTRIES LTD
|
Director
Equity Compensation
|
2025-12-02 | $0 | M | Form 4 |
|
TEVA
S
TEVA PHARMACEUTICAL INDUSTRIES LTD
MIGNONE ROBERTO
• Director
Discretionary SellΔOwn -10.1%
2025-11-26
$1,301,505Large
|
||||||
| TEVA |
TEVA PHARMACEUTICAL INDUSTRIES LTD
|
Director
Discretionary SellΔOwn -10.1%
|
2025-11-26 | $1,301,505Large | S | Form 4 |
|
TEVA
S
TEVA PHARMACEUTICAL INDUSTRIES LTD
Fox Christine
• Officer • EVP, Head of U.S. Commercial
Sell to CoverΔOwn -30.7%
2025-11-20
$699,523
|
||||||
| TEVA |
TEVA PHARMACEUTICAL INDUSTRIES LTD
|
Officer • EVP, Head of U.S. Commercial
Sell to CoverΔOwn -30.7%
|
2025-11-20 | $699,523 | S | Form 4 |
|
TEVA
S
TEVA PHARMACEUTICAL INDUSTRIES LTD
Fox Christine
• Officer • EVP, Head of U.S. Commercial
Discretionary SellΔOwn -51.4%
2025-11-14
$753,321
|
||||||
| TEVA |
TEVA PHARMACEUTICAL INDUSTRIES LTD
|
Officer • EVP, Head of U.S. Commercial
Discretionary SellΔOwn -51.4%
|
2025-11-14 | $753,321 | S | Form 4 |
|
TEVA
S
TEVA PHARMACEUTICAL INDUSTRIES LTD
MIGNONE ROBERTO
• Director
Discretionary SellΔOwn -28.8%
2025-11-06
$4,821,880Large
|
||||||
| TEVA |
TEVA PHARMACEUTICAL INDUSTRIES LTD
|
Director
Discretionary SellΔOwn -28.8%
|
2025-11-06 | $4,821,880Large | S | Form 4 |
|
TEVA
S
TEVA PHARMACEUTICAL INDUSTRIES LTD
Weiss Amir
• Officer • Chief Accounting Officer
Discretionary SellΔOwn -40.7%
2025-11-06
$300,564
|
||||||
| TEVA |
TEVA PHARMACEUTICAL INDUSTRIES LTD
|
Officer • Chief Accounting Officer
Discretionary SellΔOwn -40.7%
|
2025-11-06 | $300,564 | S | Form 4 |